Trial Profile
A Retrospective Observational Study Comparing Nivolumab + Ipilimumab Combination vs. Nivolumab Monotherapy as First Line Treatment of Metastatic PD-L1 Positive Melanoma in the US
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 06 Dec 2022 Status changed from active, no longer recruiting to completed.
- 15 Nov 2018 New trial record